Strengthening Vaccine Manufacturing in Developing Nations Through Capacity-Building

When the COVID-19 pandemic swept across the world, developing nations quickly realized a harsh truth: being dependent on others for life-saving vaccines leaves you vulnerable when global supply chains break down. Building local vaccine manufacturing capacity isn’t just about producing medicines-it’s about protecting populations when the next pandemic strikes.

Why local vaccine production matters 🔗

Developing countries face a fundamental challenge during health emergencies. While wealthy nations can secure vaccine supplies through advance purchases and bilateral agreements, resource-constrained countries often wait months or even years for access. Capacity building for vaccine manufacturing has become a paramount concern, particularly during pandemic situations when rapid response determines how many lives can be saved.

The need extends beyond emergency response. Nations that produce their own vaccines gain supply security, control over production schedules, cost management, and the ability to respond rapidly to local disease outbreaks. These benefits translate into stronger health systems and improved pandemic preparedness.

The obstacles facing developing nations 🔗

Starting vaccine production from scratch involves navigating a complex maze of challenges. The barriers begin with the need for tens or even hundreds of millions of dollars in capital investment to establish commercial production facilities. Beyond initial costs, manufacturers face regulatory barriers, demand uncertainty, and limited research funding that threaten long-term viability.

Technology transfer complications 🔗

Technology transfer represents one of the most significant hurdles. Unlike small-molecule drugs, vaccines involve complex biological processes protected by trade secrets that are never made publicly available. Over 70% of developing country vaccine manufacturers report inadequate research capacity to support effective technology transfer. Even when technology reaches these shores, significant know-how from original developers remains essential to reproduce vaccines successfully.

Regulatory and financial constraints 🔗

The regulatory environment presents another major obstacle. According to WHO estimates, only 30% of national regulators currently possess the capability to effectively oversee vaccine manufacturing and monitor vaccine safety as products reach populations. This gap limits where manufacturing expansion can realistically occur.

Financing challenges compound these difficulties. Survey data reveals that 50% of developing country manufacturers cite lack of technical expertise as a barrier, while 44% point to internal financing constraints and 38% struggle with external funding access. Training programs face their own challenges-high costs, lengthy durations, and staff turnover as personnel seek better-paying opportunities elsewhere.

Serum Institute of India: A model for success 🔗

The Serum Institute of India demonstrates what’s possible when developing nations invest in vaccine manufacturing capacity. In 2006, WHO launched the Global Action Plan for Influenza Vaccines in response to human-to-human transmission of H5N1 bird flu, calling for strengthened capacity in developing countries to produce influenza vaccines.

SII became one of six developing country manufacturers awarded grants in 2007 for technology transfers to establish influenza vaccine manufacturing capacity. The organization developed both H5N1 and H1N1 vaccine capabilities through this collaboration. When the H1N1 pandemic emerged in 2009, three developing country vaccine manufacturers readied an influenza vaccine for global use in a record nine months-a breakthrough that demonstrated how capacity building enables rapid pandemic response.

Scaling up for global impact 🔗

The institute’s success extended far beyond influenza vaccines. SII partnered with WHO and PATH to develop vaccines for African markets, including a meningitis vaccine that resulted in 100 million people being vaccinated in Sub-Saharan Africa. The company now operates facilities with annual capacity exceeding 4 billion doses, supplying vaccines to over 170 countries.

During the COVID-19 pandemic, SII transferred technology with AstraZeneca to produce Covishield, significantly improving vaccine availability in India and beyond. This collaboration illustrated how established manufacturing capacity enables countries to respond effectively when global health emergencies strike.

Building capacity for future pandemics 🔗

The path forward requires coordinated global action. Technology transfer to developing countries has contributed significantly to increasing vaccine supply, improving access, and lowering prices. However, success depends on government commitment, adequate funding, and sufficient local or regional market demand.

Emerging initiatives 🔗

New programs are addressing capacity gaps. WHO established an mRNA vaccine hub in South Africa to develop COVID-19 vaccines and transfer technology to other African countries including Egypt, Kenya, Nigeria, Senegal, and Tunisia. The African Union has called for expanded manufacturing of vaccines, diagnostics, and therapeutics to democratize access to life-saving medicines.

Platform technologies offer promising solutions. These technologies use common production mechanisms for multiple vaccines, allowing manufacturers to rapidly scale up production and switch between different products. Regulators may approve products based on platform characteristics rather than individual product reviews, substantially improving surge production capacity for future pandemics.

Investment in people and infrastructure 🔗

Sustainable capacity building requires workforce development alongside physical infrastructure. Countries need permanent multidisciplinary training programs with hands-on instruction, proper monitoring, and continuous evaluation. International partnerships can provide technical support, training sessions, online learning options, and skills-based courses that build local expertise.

Financial mechanisms must bridge critical gaps. Organizations are developing innovative financing solutions to support the period between technology transfer and regulatory approval-a phase requiring substantial investment in bioequivalence studies, equipment, and facility preparation. The $1 billion African Vaccine Manufacturing Accelerator offers financial incentives to manufacturers who achieve regulatory milestones and supply priority vaccines, de-risking investments and encouraging technology transfers.

The road ahead 🔗

Building vaccine manufacturing capacity in developing nations strengthens global health security for everyone. Countries with local production capabilities can fulfill domestic needs quickly during pandemics, then contribute to global vaccine supplies. This capacity also supports routine immunization programs that prevent millions of deaths from preventable diseases each year.

The COVID-19 pandemic exposed dangerous gaps in global vaccine access. Vaccine nationalism left significant parts of the world vulnerable as countries hoarded supplies to vaccinate their own populations first. Distributed manufacturing capacity across all regions provides insurance against this risk in future health emergencies.

Success requires continued investment in research infrastructure, regulatory strengthening, workforce training, and financial support mechanisms. It demands partnerships between governments, international organizations, pharmaceutical companies, and local manufacturers working toward shared goals of health equity and pandemic preparedness.

What do you think? How can developing nations balance the high costs of building vaccine manufacturing capacity against the security benefits of local production? What role should wealthier countries play in supporting technology transfer and capacity building initiatives?

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8986212/
2. https://www.sciencedirect.com/science/article/abs/pii/S0264410X22013056
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC7909323/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8279498/
5. https://dcvmn.org/history/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9536867/
7. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00878-7/fulltext
8. https://medaccess.org/overcoming-barriers-to-african-vaccine-manufacturing/
9. https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0002098